De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Henan Lingrui Pharmaceutical Inkomsten in het verleden
Verleden criteriumcontroles 6/6
Henan Lingrui Pharmaceutical has been growing earnings at an average annual rate of 17.6%, while the Pharmaceuticals industry saw earnings growing at 9% annually. Revenues have been growing at an average rate of 11.2% per year. Henan Lingrui Pharmaceutical's return on equity is 24.5%, and it has net margins of 18.9%.
Belangrijke informatie
17.6%
Groei van de winst
18.2%
Groei van de winst per aandeel
Pharmaceuticals Groei van de industrie | 10.9% |
Inkomstengroei | 11.2% |
Rendement op eigen vermogen | 24.5% |
Nettomarge | 18.9% |
Volgende winstupdate | 30 Oct 2024 |
Recente prestatie-updates uit het verleden
Recent updates
If EPS Growth Is Important To You, Henan Lingrui Pharmaceutical (SHSE:600285) Presents An Opportunity
Aug 07A Look At The Fair Value Of Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285)
Jul 03Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Stock Catapults 27% Though Its Price And Business Still Lag The Market
May 07Henan Lingrui Pharmaceutical's (SHSE:600285) Earnings May Just Be The Starting Point
May 02Henan Lingrui Pharmaceutical Co., Ltd. (SHSE:600285) Held Back By Insufficient Growth Even After Shares Climb 27%
Mar 04Should You Be Adding Henan Lingrui Pharmaceutical (SHSE:600285) To Your Watchlist Today?
Feb 29Opbrengsten en kosten
Hoe Henan Lingrui Pharmaceutical geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 3,517 | 664 | 1,742 | 114 |
31 Mar 24 | 3,432 | 614 | 1,717 | 109 |
31 Dec 23 | 3,311 | 568 | 1,680 | 110 |
30 Sep 23 | 3,232 | 526 | 1,667 | 123 |
30 Jun 23 | 3,200 | 512 | 1,678 | 126 |
31 Mar 23 | 3,108 | 479 | 1,651 | 126 |
31 Dec 22 | 3,002 | 465 | 1,610 | 125 |
30 Sep 22 | 2,917 | 440 | 1,581 | 92 |
30 Jun 22 | 2,841 | 412 | 1,564 | 89 |
31 Mar 22 | 2,786 | 396 | 1,523 | 95 |
31 Dec 21 | 2,694 | 362 | 1,485 | 86 |
30 Sep 21 | 2,635 | 383 | 1,475 | 110 |
30 Jun 21 | 2,513 | 368 | 1,411 | 102 |
31 Mar 21 | 2,430 | 346 | 1,398 | 100 |
31 Dec 20 | 2,332 | 325 | 1,342 | 98 |
30 Sep 20 | 2,215 | 302 | 1,260 | 94 |
30 Jun 20 | 2,163 | 288 | 1,232 | 88 |
31 Mar 20 | 2,068 | 270 | 1,178 | 78 |
31 Dec 19 | 2,157 | 294 | 1,223 | 79 |
30 Sep 19 | 2,149 | 292 | 1,225 | 63 |
30 Jun 19 | 2,118 | 280 | 1,212 | 65 |
31 Mar 19 | 2,078 | 270 | 1,201 | 57 |
31 Dec 18 | 2,053 | 243 | 1,172 | 58 |
30 Sep 18 | 2,139 | 240 | 1,255 | 50 |
30 Jun 18 | 2,120 | 230 | 1,200 | 75 |
31 Mar 18 | 1,990 | 223 | 1,099 | 67 |
31 Dec 17 | 1,849 | 217 | 1,014 | 56 |
30 Sep 17 | 1,697 | 198 | 882 | 35 |
30 Jun 17 | 1,608 | 381 | 860 | 0 |
31 Mar 17 | 1,513 | 364 | 811 | 0 |
31 Dec 16 | 1,439 | 346 | 767 | 0 |
30 Sep 16 | 1,315 | 365 | 672 | 0 |
30 Jun 16 | 1,225 | 152 | 614 | 0 |
31 Mar 16 | 1,133 | 141 | 562 | 0 |
31 Dec 15 | 1,085 | 132 | 519 | 0 |
30 Sep 15 | 1,006 | 119 | 481 | 0 |
30 Jun 15 | 936 | 115 | 442 | 0 |
31 Mar 15 | 901 | 97 | 439 | 0 |
31 Dec 14 | 826 | 76 | 410 | 0 |
30 Sep 14 | 802 | 75 | 396 | 0 |
30 Jun 14 | 757 | 65 | 365 | 0 |
31 Mar 14 | 718 | 59 | 336 | 0 |
31 Dec 13 | 687 | 105 | 318 | 0 |
Kwaliteitswinsten: 600285 has high quality earnings.
Groeiende winstmarge: 600285's current net profit margins (18.9%) are higher than last year (16%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 600285's earnings have grown by 17.6% per year over the past 5 years.
Versnelling van de groei: 600285's earnings growth over the past year (29.8%) exceeds its 5-year average (17.6% per year).
Winst versus industrie: 600285 earnings growth over the past year (29.8%) exceeded the Pharmaceuticals industry -0.6%.
Rendement op eigen vermogen
Hoge ROE: 600285's Return on Equity (24.5%) is considered high.